AR124712A1 - Composiciones de anticuerpos del receptor de muerte programada 1 (pd-1) y métodos para obtener las composiciones de los mismos - Google Patents

Composiciones de anticuerpos del receptor de muerte programada 1 (pd-1) y métodos para obtener las composiciones de los mismos

Info

Publication number
AR124712A1
AR124712A1 ARP220100165A ARP220100165A AR124712A1 AR 124712 A1 AR124712 A1 AR 124712A1 AR P220100165 A ARP220100165 A AR P220100165A AR P220100165 A ARP220100165 A AR P220100165A AR 124712 A1 AR124712 A1 AR 124712A1
Authority
AR
Argentina
Prior art keywords
seq
species
antibody
heavy chain
human
Prior art date
Application number
ARP220100165A
Other languages
English (en)
Inventor
Mark A Brower
Chung Huang
- Kwan Brian Wai Jr
William Nicholas Napoli
Bhumit A Patel
Santos Pinto Nuno J Dos
Ii Douglas Dennis Richardson
Sen Xu
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR124712A1 publication Critical patent/AR124712A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención proporciona composiciones de anticuerpos anti-PD-1 o fragmentos de unión a antígeno de los mismos con menos de, o igual a, aproximadamente un 3,0% de oxidación de Met105 en la región de cadena pesada de CDRH3, y métodos para obtener las composiciones purificadas. La invención también proporciona composiciones que comprenden especies principales de anticuerpos anti-PD-1 y especies ácidas de los mismos, en donde la cantidad de especies ácidas es de aproximadamente 1,0 - 12,0%. Reivindicación 1: Una composición que comprende un anticuerpo anti-PD-1 humano o un fragmento de unión al antígeno del mismo, en donde el anticuerpo anti-PD-1 humano o el fragmento de unión a antígeno del mismo comprende una región variable de cadena ligera que comprende tres CDR de cadena ligera que comprenden CDRL1 de SEQ ID Nº 1, CDRL2 de SEQ ID Nº 2 y CDRL3 de SEQ ID Nº 3 y una región variable de cadena pesada que comprende tres CDR de cadena pesada de CDRH1 de SEQ ID Nº 6, CDRH2 de SEQ ID Nº 7 y CDRH3 de SEQ ID Nº 8, en donde dicho anticuerpo o fragmento de unión a antígeno del mismo, tiene menos de, o igual a, aproximadamente un 3,0% de oxidación de Metionina 105. Reivindicación 12: Una composición que comprende una especie principal de anticuerpo anti-PD-1 humano producido a partir de una célula de ovario chino que comprende un polinucleótido que codifica una cadena ligera y un polinucleótido que codifica una cadena pesada, o un polinucleótido que codifica una cadena ligera y una cadena pesada, en donde la cadena pesada consiste en la secuencia de aminoácidos de SEQ ID Nº 10, 13 ó 15, y la cadena ligera consiste en la secuencia de aminoácidos de SEQ ID Nº 5, y especies ácidas de las especies principales del anticuerpo anti-PD-1 humano, en donde la cantidad de especies ácidas es de 1,0 - 12,0%. Reivindicación 13: Una composición que comprende una especie principal de anticuerpo anti-PD-1 humano que comprende un anticuerpo que consiste en dos cadenas pesadas y dos cadenas ligeras, consistiendo cada cadena pesada en la secuencia de aminoácidos de SEQ ID Nº 11, y consistiendo cada cadena ligera en la secuencia de aminoácidos de SEQ ID Nº 5, y especies ácidas y básicas de la especie principal del anticuerpo anti-PD-1 humano, en donde la cantidad de especies principales es de 65 - 85%.
ARP220100165A 2021-01-29 2022-01-27 Composiciones de anticuerpos del receptor de muerte programada 1 (pd-1) y métodos para obtener las composiciones de los mismos AR124712A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163143461P 2021-01-29 2021-01-29

Publications (1)

Publication Number Publication Date
AR124712A1 true AR124712A1 (es) 2023-04-26

Family

ID=80786902

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220100165A AR124712A1 (es) 2021-01-29 2022-01-27 Composiciones de anticuerpos del receptor de muerte programada 1 (pd-1) y métodos para obtener las composiciones de los mismos

Country Status (9)

Country Link
US (1) US20220251205A1 (es)
EP (1) EP4284834A1 (es)
JP (1) JP2024505524A (es)
CN (1) CN117043194A (es)
AR (1) AR124712A1 (es)
AU (1) AU2022212007A1 (es)
CA (1) CA3206669A1 (es)
TW (1) TW202237657A (es)
WO (1) WO2022165001A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024165043A1 (en) * 2023-02-08 2024-08-15 Beigene Switzerland Gmbh Preparation methods for a highly concentrated pd1 antibody solution by applying single-pass tangential flow filtration (sptff)

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
KR100483494B1 (ko) 1998-12-01 2005-04-15 프로테인 디자인 랩스 인코포레이티드 감마 인터페론에 대한 인간화 항체
WO2003086310A2 (en) 2002-04-12 2003-10-23 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
US20110142858A1 (en) 2004-06-07 2011-06-16 Ramot At Tel Aviv University Ltd. Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation
WO2008052101A2 (en) 2006-10-25 2008-05-02 President And Fellows Of Harvard College Multiplex automated genome engineering
ES2437327T3 (es) 2007-06-18 2014-01-10 Merck Sharp & Dohme B.V. Anticuerpos para el receptor PD-1 humano de muerte programada
WO2012018538A2 (en) 2010-07-26 2012-02-09 Schering Corporation Bioassays for determining pd-1 modulation
MX355624B (es) 2011-12-22 2018-04-25 Hoffmann La Roche Combinaciones de elementos de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos.
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2015016786A1 (en) 2013-08-02 2015-02-05 Agency For Science, Technology And Research Mutated internal ribosomal entry site (ires) for controlled gene expression
EP3030659A4 (en) 2013-08-05 2017-01-11 Tocagen Inc. Recombinant vector with optimized a-bulge
ES2681622T3 (es) 2013-09-18 2018-09-14 Kymab Limited Métodos, células y organismos
JP6174811B2 (ja) 2013-12-11 2017-08-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. ゲノムの標的改変のための方法及び組成物
WO2015157579A2 (en) 2014-04-09 2015-10-15 Dna2.0, Inc. Enhanced nucleic acid constructs for eukaryotic gene expression
US10344285B2 (en) 2014-04-09 2019-07-09 Dna2.0, Inc. DNA vectors, transposons and transposases for eukaryotic genome modification
WO2016003368A1 (en) 2014-07-01 2016-01-07 Agency For Science, Technology And Research Optimized vectors for the production of recombinant proteins
CA2967060A1 (en) 2014-11-10 2016-05-19 Murdoch Childrens Research Institute Vectors and methods for targeted integration in loci comprising constitutively expressed genes
US20170204446A1 (en) * 2016-01-15 2017-07-20 Artemis BioSystems Inc. System for rapid continuous manufacturing of monoclonal antibodies
US9896696B2 (en) 2016-02-15 2018-02-20 Benson Hill Biosystems, Inc. Compositions and methods for modifying genomes
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3618866A4 (en) 2017-05-02 2021-07-14 Merck Sharp & Dohme Corp. STABLE FORMULATIONS OF ANTI-CTLA4 ANTIBODIES ALONE AND IN COMBINATION WITH PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHOD OF USING THEREOF
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
SG11202004273YA (en) * 2017-12-11 2020-06-29 Amgen Inc Continuous manufacturing process for bispecific antibody products
US20220033845A1 (en) 2018-09-24 2022-02-03 Merck Sharp & Dohme Corp. Expression vectors for eukaryotic expression systems
WO2020168315A1 (en) 2019-02-15 2020-08-20 Just-Evotec Biologics, Inc. Automated biomanufacturing systems, facilities, and processes
MX2021014644A (es) * 2019-06-13 2022-04-06 Amgen Inc Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.

Also Published As

Publication number Publication date
US20220251205A1 (en) 2022-08-11
CN117043194A (zh) 2023-11-10
TW202237657A (zh) 2022-10-01
JP2024505524A (ja) 2024-02-06
WO2022165001A1 (en) 2022-08-04
EP4284834A1 (en) 2023-12-06
CA3206669A1 (en) 2022-08-04
AU2022212007A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
RU2747735C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
CL2013003140A1 (es) Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene.
PE20121579A1 (es) Proteinas de enlace al antigeno il-23 humanas
PE20090518A1 (es) Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)
AR097651A1 (es) Métodos y composiciones que comprenden polipéptidos recombinantes purificados
RU2011105062A (ru) Нейтрализующие антитела против вируса гриппа а и их использование
PE20231958A1 (es) Moleculas de union a pd-1 y metodos de uso de las mismas
HRP20170444T1 (hr) Projektirana anti-il-23 antitijela
PE20120554A1 (es) Polipeptidos y metodo de tratamiento
AR066164A1 (es) Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf)
HRP20240182T1 (hr) Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
AR100573A1 (es) Anticuerpos anti-il-17, un método para producirlos y utilizarlos
PE20170687A1 (es) Proteinas de enlace a cd127
RU2017104813A (ru) Молекулы со специфичностью к cd45 и cd79
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
RU2016129274A (ru) Канинизированные мышиные антитела к человеческому pd-1
PE20142242A1 (es) Anticuerpos humanos anti-cd27, metodos, y usos
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
AR072985A1 (es) Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union
PE20090768A1 (es) Metodos y composiciones para el tratamiento de enfermedades alergicas
RU2009129403A (ru) Антитела, нейтрализующие цитомегаловирус человека, и их применение
NZ610153A (en) Novel anti-dr5 antibody
AR123480A1 (es) Moléculas de unión terapéuticas
RU2014145536A (ru) Антитело против adamts-5, его производные и их применение
AR082194A1 (es) Anticuerpos anti-ron